Evidence map›Paper›PMID 39061619›Full record

ArticleDiagnostics (Basel, Switzerland)2024

A Comparison Study: Possible Bias in Troponin I Measurement Obtained with a Point of Care Testing and a Central Laboratory Analyzers Employing Different Biological Matrices and Anticoagulants.

Antonino Sammartano, Ruggero Buonocore, Roberto Fiorini, Elisabetta Dieci, Anna Di Franco, Bruna Di Stasi, Giovanni Tortorella, Luigi Ippolito

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Antonino SammartanoU.O. Clinical Pathology, Medical and Diagnostics Department P.O. Fidenza, Azienda AUSL of Parma, 43125 Parma, Italy.ORCID 0000-0002-1709-4758
Ruggero BuonocoreU.O. Biochemical, Department of Clinical Patology, Ospedale Guglielmo da Saliceto of Piacenza, 29121 Piacenza, Italy.ORCID 0000-0003-1897-3188
Roberto FioriniEmergency Department, Vaio Hospital, Azienda AUSL of Parma, 43125 Parma, Italy.
Elisabetta DieciU.O. Biochemical, Department of Clinical Patology, Ospedale Guglielmo da Saliceto of Piacenza, 29121 Piacenza, Italy.
Anna Di FrancoU.O. Biochemical, Department of Clinical Patology, Ospedale Guglielmo da Saliceto of Piacenza, 29121 Piacenza, Italy.
Bruna Di StasiU.O. Biochemical, Department of Clinical Patology, Ospedale Guglielmo da Saliceto of Piacenza, 29121 Piacenza, Italy.
Giovanni TortorellaCardiology Unit, Medical and Diagnostics Department P.O. Fidenza, Azienda AUSL of Parma, 43125 Parma, Italy.
Luigi IppolitoU.O. Clinical Pathology, Medical and Diagnostics Department P.O. Fidenza, Azienda AUSL of Parma, 43125 Parma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundhigh-sensitive cardiac TroponinI (hs-cTnI) is widely used for diagnosis of acute coronary syndromes. The latest recommendation for hs-cTnI determination is the protocol 0-1 h finalized to improve the rule out accuracy of the test. A Point of Care Testing able to guarantee these performances could be very useful due to reducing the turnaround time and ruling out patients suspected of ACS, especially by using biological matrices that are not required for centrifuge. The aim of our work is to compare the results for hs-cTnI obtained using different biological matrices and anticoagulants, obtained between Atellica

methodsLi-heparinized pool samples were primary employ for hs-cTnI with Atellica

resultscomparing whole blood lithium heparin results obtained with Atellica versus lithium heparin and K

conclusionsin the laboratory, the estimation of the bias of two different analyzers is pivotal. Once more this is crucial when different biological matrices and anticoagulants are employed for the analysis. Our study demonstrates that no significant differences among the two matrices are present when comparing Atellica and DxI800 performances.

Indexed as

high-sensitivitymyocardial injurypoint of caretroponin

Identifiers

PMID39061619
PMCPMC11275273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.